- Conditions
- Health Behavior
- Interventions
- Creatine Monohydrate Supplementation
- Dietary Supplement
- Lead sponsor
- University of Idaho
- Other
- Eligibility
- 18 Years to 22 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Moscow, Idaho
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 155
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Interventions
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
- Conditions
- Uterine Fibroids
- Interventions
- Proellex 25 mg, Proellex 50 mg
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • San Diego, California + 17 more
- Conditions
- Adult Idiopathic Generalized Osteoporosis
- Interventions
- Teriparatide, Saline Placebo
- Drug
- Lead sponsor
- Elizabeth Shane
- Other
- Eligibility
- 20 Years to 45 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
- Conditions
- Uterine Fibroids
- Interventions
- telepristone acetate 12 mg, telepristone acetate 3 mg, telepristone acetate 6 mg, telepristone acetate 24 mg
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 47 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Miami Gardens, Florida • Houston, Texas
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 35
- States / cities
- Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
- Conditions
- Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging
- Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 14 Years to 35 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metabolic Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Interventions
- cholecalciferol, placebo
- Dietary Supplement · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 360
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
- Conditions
- Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
- Interventions
- bremelanotide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Mammography, Questionnaire Administration, Tamoxifen
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more
- Conditions
- Overweight, Obesity
- Interventions
- Reduced calorie diet and exercise plan, Different reduced calorie diet and exercise plan
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Uterine Fibroids
- Interventions
- Elagolix, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
- Conditions
- Breast Cancer Prevention, Mammographic Density
- Interventions
- Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D
- Procedure · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer
- Interventions
- Omega-3 Supplementation
- Dietary Supplement
- Lead sponsor
- Lauren Nye
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Westwood, Kansas
- Conditions
- Breast Cancer, Fatigue, Sleep Disorders
- Interventions
- Tamoxifen, triptorelin, Exemestane
- Drug
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Network
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 13
- States / cities
- Sacramento, California • Fort Collins, Colorado • Norwalk, Connecticut + 7 more
- Conditions
- Breast Cancer, Lymphoma, Hodgkin's Lymphoma
- Interventions
- surveys, Blood draw, Transvaginal ultrasounds
- Behavioral · Other · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Bone Health, Osteoporosis
- Interventions
- Yoga Group
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Norman, Oklahoma
- Conditions
- Breast Cancer, Osteoporosis
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 3
- States / cities
- Stamford, Connecticut • Paramus, New Jersey • New York, New York
- Conditions
- Uterine Fibroids, Endometriosis
- Interventions
- Relugolix Combination Tablet
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 120
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
- Conditions
- Endometriosis
- Interventions
- Proellex 25 mg, Placebo, Proellex 50 mg
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
- Conditions
- Endometriosis
- Interventions
- Proellex®
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • San Diego, California • San Ramon, California + 4 more